[HTML][HTML] In vitro human cancer models for biomedical applications

JR Choi, G Kozalak, I Di Bari, Q Babar, Z Niknam… - Cancers, 2022 - mdpi.com
Simple Summary Cancer is a leading cause of death worldwide. While numerous studies
have been conducted on cancer treatment, clinical treatment options for cancers are still …

The importance of cancer cell lines as in vitro models in cancer methylome analysis and anticancer drugs testing

D Ferreira, F Adega, R Chaves - Oncogenomics and cancer …, 2013 - books.google.com
Cancer is a molecularly heterogeneous disease [1] and one of the major causes of death
worldwide. The existence of various types of tumours with different histopathologies, genetic …

[HTML][HTML] PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I

S Ishihara, Y Yamada, T Iwasaki… - Oncology …, 2021 - spandidos-publications.com
The prognosis of undifferentiated pleomorphic sarcoma (UPS) is generally unfavorable.
Recently, clinical trials such as SARC028 demonstrated the utility of cancer immunotherapy …

[HTML][HTML] Novel PD-L1-and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy

P Taborska, P Lukac, D Stakheev, L Rajsiglova… - Scientific Reports, 2023 - nature.com
Soft tissue sarcomas are aggressive mesenchymal-origin malignancies. Undifferentiated
pleomorphic sarcoma (UPS) belongs to the aggressive, high-grade, and least characterized …

[HTML][HTML] Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic …

H Bekki, K Kohashi, A Maekawa, Y Yamada… - BMC cancer, 2015 - Springer
Background Undifferentiated pleomorphic sarcoma (UPS) is a heterogeneous tumor group,
and little is known about molecular target therapy for UPS. Heat shock protein 90 (HSP90) is …

Phosphorylation of STAT3 in undifferentiated pleomorphic sarcoma is correlated with a favorable prognosis

H Bekki, K Kohashi, Y Yamada, K Iura, T Ishii… - Pathobiology, 2017 - karger.com
Objective: The Janus kinase (JAK)-signal transducer and activator of transcription (STAT)
pathway plays a role in various biological processes. Phosphorylated STAT3 (p-STAT3) …

Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma

MF Orth, JS Gerke, T Knösel… - … journal of cancer, 2019 - Wiley Online Library
Soft‐tissue sarcomas are rare, heterogeneous, and often aggressive mesenchymal cancers.
Many of them are associated with poor outcome, partially because biomarkers that can …

[HTML][HTML] Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating …

M Hakozaki, T Tajino, S Konno, S Kikuchi, H Yamada… - PloS one, 2014 - journals.plos.org
Background Cyclooxygenase-2 (COX-2) is a key enzyme in the conversion of arachidonic
acid to prostanoids, and its activation is associated with carcinogenesis as well as …

[HTML][HTML] Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents

M Becker, C Graf, M Tonak, MP Radsak… - Oncology …, 2016 - spandidos-publications.com
Undifferentiated pleomorphic sarcoma not otherwise specified belongs to the
heterogeneous group of soft tissue tumors. It is preferentially located in the upper and lower …

Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma

R Oyama, F Kito, M Sakumoto, K Shiozawa… - In Vitro Cellular & …, 2018 - Springer
Undifferentiated pleomorphic sarcoma (UPS) is an aggressive mesenchymal malignancy
requiring novel therapeutic approaches to improve clinical outcome. Patient-derived cancer …